Table 3.
Selected baseline characteristics: before and after Mahalanobis distance matching
| Factors | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| MONARCH 1 (N = 132) |
Real-world cohort (N = 281) |
p-value | MONARCH 1 (N = 108) |
Real-world cohort (N = 108) |
p-value | |
| Pooled age Group, n (%) | 0.031 | 1.0 | ||||
| < 65 years | 90 (68.2) | 159 (56.6) | 72 (66.7) | 71 (65.7) | ||
| ≥ 65 years | 42 (31.8) | 122 (43.4) | 36 (33.3) | 37 (34.3) | ||
| Pooled race group, n (%) | < .0001 | 0.569 | ||||
| Other | 8 (6.1) | 89 (31.7) | 8 (7.4) | 5 (4.6) | ||
| White | 124 (93.9) | 192 (68.3) | 100 (92.6) | 103 (95.4) | ||
| Lines of chemotherapya, n (%) | 0.290 | 0.783 | ||||
| 1 Regimen | 67 (50.8) | 159 (56.6) | 61 (56.5) | 64 (59.3) | ||
| 2 Regimens | 65 (49.2) | 122 (43.4) | 47 (43.5) | 44 (40.7) | ||
| Lines of prior ETa, n (%) | < .0001 | 0.984 | ||||
| 0 Regimen | 17 (12.9) | 114 (40.6) | 17 (15.7) | 16 (14.8) | ||
| 1 Regimen | 48 (36.4) | 77 (27.4) | 40 (37.0) | 42 (38.9) | ||
| 2 Regimens | 25 (18.9) | 54 (19.2) | 23 (21.3) | 24 (22.2) | ||
| 3 + Regimens | 42 (31.8) | 36 (12.8) | 28 (25.9) | 26 (24.1) | ||
| PgR Status | 0.879 | |||||
| Negative | 35 (26.5) | 99 (35.2) | .090 | 29 (26.9) | 31 (28.7) | |
| Positive | 95 (72.0) | 179 (63.7) | 79 (73.1) | 77 (71.3) | ||
| Prior capecitabine use, n (%) | < .0001 | 0.586 | ||||
| No | 56 (42.4) | 208 (74.0) | 54 (50.0) | 59 (54.6) | ||
| Yes | 76 (57.6) | 73 (26.0) | 54 (50.0) | 49 (45.4) | ||
Fisher’s exact test was used for p-value
Patients with missing baseline disease characteristics were removed from the matching protocol
ET Endocrine therapy, N total number of patients, n number of patients within a specific category, PgR progesterone receptor
aIn metastatic setting